Switzerland
Every company in the roster headquartered in Switzerland.
Every company in the roster headquartered in Switzerland.
19 of 19 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
NovartisNVS · NYSE | 89 assets: 32 approved, 13 Ph 3, 24 Ph 2, 12 Ph 1, 8 other | indacaterol maleate / mometasone furoatePhase 3 · AsthmaReliable signal | 27 Nov 2026Inclisiran · Approved | $294.9B | $11.5BDec 2025 | Cash-flow positive | $11.2B |
BeOne MedicinesONC · Nasdaq | 10 assets: 6 approved, 2 Ph 3, 2 Ph 1 | BGB-43395Phase 3 · HR+/HER2- Metastatic Breast Cancer | Nov 2026Sonrotoclax · Phase 2 | $44.9B | $5.9BSep 2026 | Cash-flow positive | $2.4B |
CRISPR TherapeuticsCRSP · Nasdaq | 4 assets: 1 approved, 2 Ph 2, 1 Ph 1 | SRSD107Phase 2 · Atherosclerotic Cardiovascular Disease | Jun 2027CTX310 · Phase 1 | $3.9B | $2.3BSep 2026 | ~24.3 qtrs | $291M |
MoonLake ImmunotherapeuticsMLTX · Nasdaq | 1 asset: 1 Ph 3 | sonelokimabPhase 3 · Psoriatic ArthritisReliable signal | 4 Jan 2027sonelokimab · Phase 3 | $875M | $501MSep 2026 | ~8.2 qtrs | $230M |
AC ImmuneACIU · Nasdaq | 3 assets: 3 Ph 2 | ACI-35.030Phase 2 · Alzheimer's DiseasePartial signal | 22 Dec 2026ACI-35.030 · Phase 2 | $214M | $115MDec 2025 | ~5.5 qtrs | $68M |
GaldermaGALD · SIX | 1 asset: 1 approved | Approved assets only | Dec 2026nemolizumab · Phase 2 | — | — | — | — |
Idorsia PharmaceuticalsIDIA · SIX | 1 asset: 1 approved | Approved assets only | None on record | — | $119MMar 2026 | Ended Oct 2026 | $123M |
Molecular PartnersMOLN · | 2 assets: 2 Ph 1 | MP0310Phase 1 · Advanced Solid Tumors | None on record | — | $117MDec 2025 | ~7.6 qtrs | $48M |
RocheRHHBY · OTC | 68 assets: 23 approved, 20 Ph 3, 7 Ph 2, 4 Ph 1, 14 other | astegolimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal | Nov 2026Venetoclax · Phase 2 | —no price since 18 Aug 2026 | — | — | $14.7B |
Alentis Therapeutics AGPrivate | 2 assets: 2 Ph 2 | ALE.P02Phase 1/2 · Non-Small Cell Lung Cancer | 15 Feb 2028ALE.P02 · Phase 1/2 | — | — | — | — |
Bioeq AGPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Corteria PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | Corteria COR-1167Phase 2 · Heart Failure | Jul 2027Corteria COR-1167 · Phase 2 | — | — | — | — |
iOncturaPrivate | 1 asset: 1 Ph 2 | roginolisibPhase 2 · Uveal Melanoma | Jan 2027roginolisib · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 1 | NI-1801Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
SinteticaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
SQ InnovationPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Tillotts Pharma AGPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
Vifor PharmaPrivate | 7 assets: 5 approved, 1 Ph 3, 1 Ph 2 | PatiromerPhase 3 · Chronic Kidney DiseasePartial signal | Mar 2027sparsentan · Approved | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.